TITLE

The efficiency of cardiovascular risk assessment: do the right patients get statin treatment?

AUTHOR(S)
van Staa, Tjeerd-Pieter; Smeeth, Liam; Ng, Edmond S-W; Goldacre, Ben; Gulliford, Martin
PUB. DATE
November 2013
SOURCE
Heart;Nov2013, Vol. 99 Issue 21, p1597
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective To evaluate targeting of statin prescribing for primary prevention to those with high cardiovascular disease (CVD) risk. Design Two cohort studies including the general population and initiators of statins aged 35-74 years. Setting UK primary care records in the Clinical Practice Research Datalink. Patients 3.8 million general population patients and 300 914 statin users. Intervention Statin prescribing. Main outcome measures Statin prescribing by CVD risk; observed 5-year CVD risks; variability between practices. Results Statin prescribing increased substantially over time to patients with high 10-year CVD risk (=20%): 7.0% of these received a statin prior to 2007, and 30.4% in 2007 onwards. Prescribing to patients with low risk (<15%) also increased (from 1.9% to 5.0%). Only about half the patients initiating statin treatment were high risk according to CVD risk score. The 5-year CVD risks, as observed during statin treatment, reduced over calendar time (from 17.0% to 7.1%). There was a large variation between general practices in the percentage of high-risk patients prescribed a statin in 2007 onwards, ranging from 8.2% to 61.5%. For lowrisk patients, these varied from 2.1% to 29.1%. Conclusions There appeared to be substantive overuse in low CVD risk and underuse in high CVD risk (600 000 and 850 000 patients, respectively, in the UK since 2007). There is wide variation between practices in statin prescribing to patients at high CVD risk. There is a clear need for randomised trials for the best strategy to target statin treatment and manage CVD risk for primary prevention.
ACCESSION #
91025508

 

Related Articles

  • Statin Alternatives. Danavi, Joseph V.; Memon, Shermeen B.; Phan, Binh An P. // Alternative & Complementary Therapies;Oct2015, Vol. 21 Issue 5, p198 

    As the leading cause of death worldwide, cardiovascular disease has several modifiable risk factors, specifically dyslipidemia. Statin therapy has long been the mainstay treatment for dyslipidemia and has been demonstrated in various clinical trials to produce significant reductions in both...

  • Estimating treatment effects for individual patients based on the results of randomised clinical trials. Dorresteijn, Johannes A. N.; Visseren, Frank L. J.; Ridker, Paul M.; Wassink, Annemarie M. J.; Paynter, Nina P.; Steyerberg, Ewout W.; van der Graaf, Yolanda; Cook, Nancy R. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;10/22/2011, Vol. 343 Issue 7828, p836 

    No abstract available.

  • Statine nach abgesetzter Therapie meist wieder gut toleriert. Steurer, Johann // Praxis (16618157);6/19/2013, Vol. 102 Issue 13, p813 

    No abstract available.

  • Statins for the primary prevention of cardiovascular disease. Ebrahim, Shah; Taylor, Fiona C.; Brindle, Peter // BMJ: British Medical Journal;2/8/2014, Vol. 348 Issue 7944, p32 

    The article focuses on statins, indicated for secondary prevention of cardiovascular disease. It cites a review of statins by the Cholesterol Treatment Trialists Collaboration for both primary and secondary prevention which reported a 20% relative risk reduction per 1 mmol/L reduction in LDL...

  • Statins: The cause of much confusion. Hummerston, Gemma // British Journal of Cardiac Nursing;Jul2014, Vol. 9 Issue 7, p317 

    The author talks about the British National Institute for Health and Care Excellence draft on statin prescription and the debates that followed it because of the changes. She discusses the tweet she sent out from the "British Journal of Cardiac Nursing" Twitter account on the subject, and her...

  • 2014 - Adding niacin plus laropiprant to statins did not reduce vascular events and increased serious adverse events. Bloomfield, Hanna E. // ACP Journal Club;11/1/2014, Vol. 161 Issue 10, p1 

    The article offers information on the effects of extended-released (ER) drugs Niacin and Laropiprant when added to statin therapy of patients suffering from major vascular events (MVEs). It mentions the inclusion criteria of the study including patients with diabetes mellitus, myocardial...

  • Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. Macedo, Ana Filipa; Taylor, Fiona Claire; Casas, Juan P.; Adler, Alma; Prieto-Merino, David; Ebrahim, Shah // BMC Medicine;2014, Vol. 12 Issue 1, p1 

    Background Efficacy of statins has been extensively studied, with much less information reported on their unintended effects. Evidence from randomized controlled trials (RCTs) on unintended effects is often insufficient to support hypotheses generated from observational studies. We aimed to...

  • Effect of dietary pulse intake on established therapeutic lipid targets for cardiovascular risk reduction: a systematic review and meta-analysis of randomized controlled trials. Ha, Vanessa; Sievenpiper, John L.; de Souza, Russell J.; Jayalath, Viranda H.; Mirrahimi, Arash; Agarwal, Arnav; Chiavaroli, Laura; Blanco Mejia, Sonia; Sacks, Frank M.; Di Buono, Marco; Bernstein, Adam M.; Leiter, Lawrence A.; Kris-Etherton, Penny M.; Vuksan, Vladimir; Bazinet, Richard P.; Josse, Robert G.; Beyene, Joseph; Kendall, Cyril W. C.; Jenkins, David J. A. // CMAJ: Canadian Medical Association Journal;5/13/2014, Vol. 186 Issue 8, pE252 

    Background: Evidence from controlled trials encourages the intake of dietary pulses (beans, chickpeas, lentils and peas) as a method of improving dyslipidemia, but heart health guidelines have stopped short of ascribing specific benefits to this type of intervention or have graded the beneficial...

  • Project hÉ™li?dx/Healthy Hearts Across Generations: Development and Evaluation Design of a Tribally Based Cardiovascular Disease Prevention Intervention for American Indian Families. Walters, Karina; LaMarr, June; Levy, Rona; Pearson, Cynthia; Maresca, Teresa; Mohammed, Selina; Simoni, Jane; Evans-Campbell, Teresa; Fredriksen-Goldsen, Karen; Fryberg, Sheryl; Jobe, Jared // Journal of Primary Prevention;Aug2012, Vol. 33 Issue 4, p197 

    American Indian and Alaska Native (AIAN) populations are disproportionately at risk for cardiovascular disease (CVD), diabetes, and obesity, compared with the general US population. This article describes the həli?dx/Healthy Hearts Across Generations project, an AIAN-run, tribally based...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics